Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries

• Egile Nagusiak: Mojca Maticic (Egilea), Jerneja Videcnik Zorman (Egilea), Sergeja Gregorcic (Egilea), Eberhard Schatz (Egilea), Jeffrey V. Lazarus (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2019-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Hepatitis C virus (HCV) infection is the leading cause of cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC) worldwide. In Europe, people who inject drugs (PWID) represent the majority of HCV infections, but are often excluded from treatment. The aim of this st...